27542789|t|Transfemoral aortic valve implantation with the repositionable Lotus valve for treatment of patients with symptomatic severe aortic stenosis: results from a single-centre experience
27542789|a|The aim of the study was to evaluate the procedural and 30- day results for the repositionable Lotus valve in patients undergoing transfemoral aortic valve implantation in a single-centre experience. We prospectively enrolled 110 patients with severe symptomatic aortic stenosis (NCT02162069). All procedures were performed without general anaesthesia by the transfemoral approach. Patients were followed for 30 days. Patients received the 23 mm (n=20), 25 mm (n=43) or 27 mm (n=47) Lotus device. Mean oversizing in relation to annulus or left ventricular outflow tract (LVOT) did not differ among groups. There was no residual moderate or severe aortic regurgitation. The rate of mild aortic regurgitation was low at 9.1%. There was no valve embolisation, no need for a second valve and no conversion to surgery. The need for a new pacemaker implantation due to complete (third degree) or type II (Mobitz) second degree atrioventricular block was 24.1%, excluding patients with previously implanted devices. Within 30 days the rates of all-cause mortalit y and stroke were low. In patients with severe aortic stenosis, transfemoral TAVI with the repositionable Lotus valve was associated with a high rate of device success, no moderate or severe residual aortic regurgitation, low rates of major vascular complications and mortality within 30 days.
27542789	0	38	Transfemoral aortic valve implantation	T061	C0021107
27542789	48	74	repositionable Lotus valve	T074	C0184252
27542789	79	88	treatment	T061	C0087111
27542789	92	100	patients	T101	C0030705
27542789	106	117	symptomatic	T169	C0231220
27542789	118	124	severe	T080	C0205082
27542789	125	140	aortic stenosis	T047	C0003507
27542789	142	149	results	T169	C1274040
27542789	157	181	single-centre experience	T041	C0237607
27542789	197	202	study	T062	C2603343
27542789	210	218	evaluate	T058	C0220825
27542789	242	245	day	T079	C0439228
27542789	246	253	results	T169	C1274040
27542789	262	288	repositionable Lotus valve	T074	C0184252
27542789	292	300	patients	T101	C0030705
27542789	312	350	transfemoral aortic valve implantation	T061	C0021107
27542789	356	380	single-centre experience	T041	C0237607
27542789	412	420	patients	T101	C0030705
27542789	426	432	severe	T080	C0205082
27542789	433	444	symptomatic	T169	C0231220
27542789	445	460	aortic stenosis	T047	C0003507
27542789	462	473	NCT02162069	T170	C3274381
27542789	480	490	procedures	T169	C2700391
27542789	514	533	general anaesthesia	T061	C0002915
27542789	541	562	transfemoral approach	T061	C0087111
27542789	564	572	Patients	T101	C0030705
27542789	594	598	days	T079	C0439228
27542789	600	608	Patients	T101	C0030705
27542789	609	617	received	T080	C1514756
27542789	665	677	Lotus device	T074	C0184252
27542789	679	694	Mean oversizing	T081	C0392762
27542789	710	717	annulus	T026	C2262860
27542789	721	751	left ventricular outflow tract	T023	C4284103
27542789	753	757	LVOT	T023	C4284103
27542789	780	786	groups	T078	C0441833
27542789	798	809	no residual	UnknownType	C0746917
27542789	810	818	moderate	T080	C0205081
27542789	822	828	severe	T080	C0205082
27542789	829	849	aortic regurgitation	T047	C0003504
27542789	855	888	rate of mild aortic regurgitation	T081	C0392762
27542789	868	888	aortic regurgitation	T047	C0003504
27542789	919	924	valve	T023	C0003501
27542789	925	937	embolisation	T061	C0190360
27542789	953	959	second	T081	C0205436
27542789	960	965	valve	T023	C0003501
27542789	970	983	no conversion	T033	C0243095
27542789	987	994	surgery	T061	C0543467
27542789	1015	1037	pacemaker implantation	T061	C0189842
27542789	1045	1053	complete	T047	C0151517
27542789	1055	1067	third degree	T047	C0151517
27542789	1072	1125	type II (Mobitz) second degree atrioventricular block	T047	C0155700
27542789	1147	1155	patients	T101	C0030705
27542789	1172	1189	implanted devices	T061	C0948629
27542789	1201	1205	days	T079	C0439228
27542789	1210	1215	rates	T081	C1521828
27542789	1219	1237	all-cause mortalit	T081	C0205848
27542789	1244	1250	stroke	T047	C0038454
27542789	1256	1259	low	T080	C0205251
27542789	1264	1272	patients	T101	C0030705
27542789	1278	1284	severe	T080	C0205082
27542789	1285	1300	aortic stenosis	T047	C0003507
27542789	1302	1319	transfemoral TAVI	T061	C3509486
27542789	1329	1355	repositionable Lotus valve	T074	C0184252
27542789	1360	1375	associated with	T080	C0332281
27542789	1378	1382	high	T080	C0205250
27542789	1383	1387	rate	T081	C1521828
27542789	1391	1397	device	T074	C0025080
27542789	1398	1405	success	T080	C0679864
27542789	1410	1418	moderate	T080	C0205081
27542789	1422	1428	severe	T080	C0205082
27542789	1429	1437	residual	T080	C1609982
27542789	1438	1458	aortic regurgitation	T047	C0003504
27542789	1460	1463	low	T080	C0205251
27542789	1464	1469	rates	T081	C1521828
27542789	1473	1478	major	T080	C0205164
27542789	1479	1501	vascular complications	T047	C1393529
27542789	1506	1515	mortality	T081	C0205848
27542789	1526	1530	days	T079	C0439228